双受体激动 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-06-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
| Property | Value | Notes |
|---|---|---|
| 分子类型 | 合成修饰肽 | 39 个氨基酸，含脂肪酸侧链 |
| 受体靶点 | GIP 与 GLP-1 受体 | 双重激动剂 |
| 分子量 | 约 4.8 kDa | 以游离肽计 |
| 外观 | 白色至类白色粉末 | 冻干形态常见 |
| 溶解性 | 可溶于水及水性缓冲液 | 溶解后宜低温保存 |
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
=== Database design and build === For a clinical trial utilizing an electronic CRF, database design and CRF design are closely linked. The electronic CRF enables entry of data into an underlying relational database. For a clinical trial utilizing a paper CRF, the relational database is built separately. In both cases, the relational database allows entry of all data captured on the Case report form.
== History == Proinsulin C-peptide was first described in 1967 in connection with the discovery of the insulin biosynthesis pathway. Isolation of bovin C-peptide, determination of sequence, preparation of human C-peptide were done in 1971. C-peptide serves as a linker between the A- and the B- chains of insulin and facilitates the efficient assembly, folding, and processing of insulin in the endoplasmic reticulum. Equimolar amounts of C-peptide and insulin are then stored in secretory granules of the pancreatic beta cells and both are eventually released to the portal circulation. Initially, the sole interest in C-peptide was as a marker of insulin secretion and has, as such, been of great value in furthering the understanding of the pathophysiology of type 1 and type 2 diabetes. The first documented use of the C-peptide test was in 1972. In the first decade of 21st century, C-peptide has been found to be a bioactive peptide in its own right, with effects on microvascular blood flow and tissue health.
== Tuftsin analogues == Tuftsin sequence appears in all four classes of IgG. However, only leukokinin, a small fraction of IgG1, displays tuftsin activity. Tuftsin occurs in guinea pig IgG2 exactly in the same position. The mouse IgG1 analogue is a tetrapeptide Thr-Gln-Pro-Arg (TQPR) at the same place, one base change at the first base of the triplet code. Tuftsin sequence appears in residues 9-12 from the amino terminal of p12 protein of Rauscher murine leukemia virus. The tetrapeptide Thr-Arg-Pro-Lys (TRPK) is in the influenza hemagglutinin virus protein, residues 214–217. The canine analogue is the tetrapeptide Thr-Lys-Pro-Lys (TKPK). The peptide Thr-Arg-Pro-Arg (TRPR) is a biologically active pancreatic polypeptide 32–35 with gastrointestinal functions. Thr-Arg-Pro-Arg, Thr-Lys-Pro-Lys, Thr-Arg-Pro-Lys are as active as Thr-Lys-Pro-Arg. Thr-Lys-Pro-Pro-Arg (TKPPR) is a potent inhibitor. Lys-Pro-Pro-Arg (KPPR) is also an inhibitor of phagocytosis, superoxide anion production and chemotaxis both human and rat PMN leukocytes and monocytes. Tyr-Lys-Pro exert considerable regulatory effect on several macrophage functions including: phagocytosis, cell locomotion, superoxide anion production, IgE-dependent cellular cytotoxicity, β-glycuronidase release, and IL-1 production. Selank is an elongated version of tuftsin with a Pro-Gly-Pro appended, i.e. Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP). It has been claimed to have anti-anxiety and nootropic effects and is used in Russia and other former Soviet bloc countries.
Sources: en.wikipedia.org
Another common demonstration is suspending a ball in a jet or plume of air. It is often claimed that this is due to the air in the plume having lower pressure since it is moving faster. However, the air in the plume has the same pressure as the surrounding air. The ball remains in the plume since as it moves away from the center of the plume it experiences an asymmetric air flow which pushes it back toward the center. Other common classroom demonstrations, such as blowing between two suspended spheres, or inflating a large bag are sometimes explained in a similarly misleading manner by saying "faster moving air has lower pressure".
This form of asexual reproduction, called parthenogenesis, occurs in several species of gecko, and is particularly widespread in the teiids (especially Aspidocelis) and lacertids (Lacerta). In captivity, Komodo dragons (Varanidae) have reproduced by parthenogenesis. Parthenogenetic species are suspected to occur among chameleons, agamids, xantusiids, and typhlopids. Some reptiles exhibit temperature-dependent sex determination (TDSD), in which the incubation temperature determines whether a particular egg hatches as male or female. TDSD is most common in turtles and crocodiles, but also occurs in lizards and tuatara. To date, there has been no confirmation of whether TDSD occurs in snakes.
A trial with the primary objective of showing that the response to the investigational product is not clinically inferior to a comparative agent (active or placebo control). (ICH E9) Nonrandomized clinical trial
Soy protein products can be good substitutes for animal products because, unlike some other beans, soy offers a 'complete' protein profile. ... Soy protein products can replace animal-based foods—which also have complete proteins but tend to contain more fat, especially saturated fat—without requiring major adjustments elsewhere in the diet. Although soybeans have high protein content, soybeans also contain high levels of protease inhibitors, which can prevent digestion. Protease inhibitors are reduced by cooking soybeans, and are present in low levels in soy products such as tofu and soy milk. The Protein Digestibility Corrected Amino Acid Score (PDCAAS) of soy protein is the nutritional equivalent of meat, eggs, and casein for human growth and health. Soybean protein isolate has a biological value of 74, whole soybeans 96, soybean milk 91, and eggs 97.
Sources: en.wikipedia.org
=== Disorders of fluid, electrolyte, and acid-base balance === 276 Disorders of fluid, electrolyte, and acid-base balance 276.0 Hypernatremia 276.1 Hyponatremia 276.2 Acidosis 276.3 Alkalosis 276.4 Mixed acid-base balance disorder 276.5 Dehydration 276.52 Hypovolemia 276.7 Hyperkalemia 276.8 Hypokalemia
Mercenaries and multinational corporations such as Chiquita Brands International are some of the international actors that have contributed to the violence of the conflict. Beginning in the mid-1970s Colombian drug cartels became major producers, processors and exporters of illegal drugs, primarily marijuana and cocaine. On 4 July 1991, a new Constitution was promulgated. The changes generated by the new constitution are viewed as positive by Colombian society.
== Product development == Zealand Pharma does not promote and sell products in the market themselves, however, they form partnerships with several international pharmaceutical companies, who are responsible for placing the products on the market. Zealand Pharma is mostly known and recognized for the diabetes medication Lyxumia, which has been developed in collaboration with the French pharmaceutical company Sanofi. Since 2014, Zealand Pharma has collaborated with the coronary care unit at Rigshospitalet in Copenhagen developing the medication Danegaptid, which should serve the purpose of preventing injuries in the tissue of the heart, frequently seen among angioplasty patients. Furthermore, they are developing several orphan drugs with government assistance. Because of the acquisition of the Canadian Encycle Therapeutics, Zealand Pharma now also possesses the right to develop and sell the pre-clinical candidate medication ET3764, which is also being developed for the treatment of diseases of the alimentary tract.
== Dietary recommendations == In 2000, the then U.S. Institute of Medicine (now the National Academy of Medicine, NAM) updated its Estimated Average Requirements (EARs) and Recommended Dietary Allowances (RDAs) for molybdenum. If there is not sufficient information to establish EARs and RDAs, an estimate designated Adequate Intake (AI) is used instead. An AI of 2 micrograms (μg) of molybdenum per day was established for infants up to 6 months of age, and 3 μg/day from 7 to 12 months of age, both for males and females. For older children and adults, the following daily RDAs have been established for molybdenum: 17 μg from 1 to 3 years of age, 22 μg from 4 to 8 years, 34 μg from 9 to 13 years, 43 μg from 14 to 18 years, and 45 μg for persons 19 years old and older. All these RDAs are valid for both sexes. Pregnant or lactating females from 14 to 50 years of age have a higher daily RDA of 50 μg of molybdenum. As for safety, the NAM sets tolerable upper intake levels (ULs) for vitamins and minerals when evidence is sufficient. In the case of molybdenum, the UL is 2000 μg/day. Collectively the EARs, RDAs, AIs and ULs are referred to as Dietary Reference Intakes (DRIs). The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL are defined the same as in the United States. For women and men ages 15 and older, the AI is set at 65 μg/day. Pregnant and lactating women have the same AI.
=== Marriage and family === Sanger married Margaret Joan Howe (not to be confused with Margaret Sanger, the American pioneer of birth control) in 1940. She died in 2012. They had three children—Robin, born in 1943, Peter born in 1946 and Sally Joan born in 1960. He said that his wife had "contributed more to his work than anyone else by providing a peaceful and happy home."
Sources: en.wikipedia.org
它属于合成修饰肽，同时激动 GIP 与 GLP-1 两种肠促胰素受体。这类分子通常被称为双重肠促胰素受体激动剂，与选择性 GLP-1 激动剂在靶点范围上不同。
分子上的脂肪酸侧链使其与血浆白蛋白结合增强，显著延长循环半衰期。半衰期延长后，稳定血药浓度可在较长的给药间隔内维持，因此常见用法为每周一次。
同时激活两条肠促胰素通路可能在胰岛素分泌、胃排空和食欲调节上产生叠加效应。与单靶点相比，临床研究中观察到的血糖与体重变化幅度通常更明显，但各通路的具体贡献比例尚无定论。
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.